NASDAQ:ATHE Alterity Therapeutics H1 2026 Earnings Report $4.11 -0.04 (-0.96%) Closing price 06/11/2026 04:00 PM EasternExtended Trading$4.14 +0.03 (+0.73%) As of 06/11/2026 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alterity Therapeutics EPS ResultsActual EPS-$0.18Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAlterity Therapeutics Revenue ResultsActual Revenue$0.93 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlterity Therapeutics Announcement DetailsQuarterH1 2026Date1/31/2026TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsAlterity Therapeutics' Q4 2026 TU earnings is estimated for Friday, August 28, 2026, based on past reporting schedulesConference Call ResourcesInterim ReportEarnings HistoryCompany ProfilePowered by Earnings DocumentsInterim report Alterity Therapeutics Earnings HeadlinesALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System AtrophyJune 9 at 8:37 AM | finanznachrichten.deAlterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System AtrophyJune 9 at 7:05 AM | globenewswire.comIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analyst Lance Ippolito says the real opportunity is elsewhere. He's identified 5 dirt-cheap stocks at the forefront of this mega-IPO, including a space ticker that Goldman Sachs, BlackRock, and Morgan Stanley are all buying, a rare resource miner Elon's entire empire depends on, and the chip supplier Starlink satellites can't function without. Access his free SpaceX Investing Blackbook before IPO day arrives. | InvestPub (Ad)Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System AtrophyMay 19, 2026 | globenewswire.comAlterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System AtrophyMay 11, 2026 | globenewswire.comAlterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026May 7, 2026 | globenewswire.comSee More Alterity Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alterity Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alterity Therapeutics and other key companies, straight to your email. Email Address About Alterity TherapeuticsAlterity Therapeutics (NASDAQ:ATHE) is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation. Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials. Another key program, PBT434, is an oral small molecule aimed at modulating metal-mediated oxidative stress, currently in early-stage development for Parkinson’s disease and related disorders. Originally established in 1998 as Neuren Pharmaceuticals, the company rebranded to Alterity Therapeutics in 2023 to reflect its distinct focus on neurodegenerative conditions. Headquartered in Australia, Alterity conducts global clinical studies across North America, Europe and Australia, leveraging strategic partnerships to advance its pipeline toward regulatory milestones.View Alterity Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Spotify's "North Star" Outlook Was Music to Investors EarsCracker Barrel Surges 23% as Earnings Beat Signals Turnaround ProgressChewy’s Growth Engine Is Stronger Than the Market ThinksCasey’s Is Looking Like a Hot Buy as Growth, Buybacks, and Guidance AlignThe “Duck Stock” Keeps Quietly Making Money for ShareholdersEverpure: AI Storage Uncertainty Overshadows Breakneck GrowthAs Shares Fall, Analyst Are Boosting their Broadcom Price Targets Upcoming Earnings Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
